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ABSTRACT
Introduction Parkinson’s disease (PD) is a progressive 
neurodegenerative condition affecting approximately 
185,000 people in the UK. No drug has been proven to 
slow disease progression. Epidemiological and pre-clinical 
data support simvastatin, a widely used cholesterol-
lowering drug with a well-established safety profile, 
having neuroprotective properties. The aim of this study 
(Simvastatin as a neuroprotective treatment for PD (PD 
STAT)) is to determine whether simvastatin has the 
potential to slow PD progression. The study is part of the 
International Linked Clinical Trials initiative coordinated 
by The Cure Parkinson’s Trust. This paper describes the 
protocol for the PD STAT study.
Methods and analysis PD STAT is a double-blind, 
randomised, placebo-controlled, multi-centre, parallel 
group, futility trial in patients with PD of mild–moderate 
severity. 235 participants have been recruited and 
randomly allocated in a 1:1 ratio to receive either oral 
simvastatin or matched placebo. Treatment involves a 
1-month low-dose phase (40 mg daily), followed by a 
23-month high-dose phase (80 mg daily) and ends with 
a 2-month washout period. Participants are reviewed at 
clinic visits at 1 month, 6, 12, 18, 24 and 26 months post-
baseline, with interim telephone follow-up to monitor for 
adverse events.
The primary outcome is the change in the Movement 
Disorder Society Unified Parkinson’s Disease Rating Scale 
part III motor subscale score in the practically defined OFF 
medication state (OFF state) between baseline and 24 
months. Primary analysis will be on a modified intention 
to treat basis and will include only those participants who 
progress to the high-dose phase of the study.
Ethics and dissemination The protocol has been 
approved by the North East–Newcastle and North 
Tyneside 2 Research Ethics Committee. The results will 
be disseminated via research articles in peer-reviewed 
journals and presentations at local, national and 
international scientific meetings, as well as disseminated 
via patient groups, websites and networks. A summary of 
the study findings will be posted to participants at the end 
of the study.
Trial Registration ISRCTN16108482 (prospectively 
registered); EudraCT 2015-000148-40;  ClinicalTrials. gov 
NCT02787590; Pre-results.
INTRODUCTION
Parkinson’s disease (PD) is a progressive 
neurodegenerative condition affecting 
approximately one person in every 350 in the 
UK.1 Furthermore, with population growth 
and an increasingly ageing population, the 
estimated prevalence and incidence of PD in 
the UK are increasing. There are currently 
no known treatments that slow the rate of 
neuronal loss or clinical progression in PD. All 
currently licensed therapies are symptomatic.
Epidemiological and pre-clinical data 
support a possible neuroprotective role for 
statins in PD, with statin use being associated 
with lower PD incidence.2 3 Simvastatin has 
been shown in various toxin and genetic cell 
culture and rodent PD models to influence 
several pathways thought to be of relevance in 
PD etiopathogenesis, including inflammation 
Strengths and limitations of this study
 ► Independent, blinded outcome assessors not in-
volved in participant treatment, reduces likelihood 
of bias in results.
 ► OFF state Movement Disorder Society Unified 
Parkinson’s Disease Rating Scale assessments, 
the current gold standard for evaluating disease 
progression.
 ► Standardised training for raters reduces inter-rater 
variability.
 ► Embedded substudy to evaluate the participant’s tri-
al experience and inform future trial design.
 ► Long duration of study increases risk of drop-out/
loss to follow-up.
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and microglial activation, oxidative stress and α-synu-
clein aggregation.4 5 A beneficial effect of simvastatin 
on dopamine neuron survival and motor function has 
been observed in acute6 and chronic4 1-methyl-4-phe-
nyl-1,2,3,6-tetrahydropyridine mouse models. Addition-
ally, statins may have symptomatic effects on dyskinesia 
and depression in PD.4 Interestingly, simvastatin has been 
shown to reduce the rate of brain atrophy in secondary 
progressive multiple sclerosis,7 and it is likely that some of 
the mechanisms underlying neuronal death are similar in 
this and other neurodegenerative diseases. This finding 
therefore lends support to investigating the potential 
long-term disease-modifying effects of simvastatin in PD. 
In 2012, the International PD Linked Clinical Trials initia-
tive (LCT) was established by The Cure Parkinson’s Trust 
to identify potential new neuroprotective treatments for 
PD by repurposing drugs that have been approved, or 
are in current clinical development, to treat other condi-
tions.8 On the basis that simvastatin has a well-established 
safety profile,9 10 it was one of the first drugs selected by the 
LCT committee to be tested in a clinical trial in patients 
with PD to determine its disease-modifying potential.
Clinical trials of potential neuroprotective agents in 
PD are difficult to design, given the variability in disease 
phenotype and rate of progression, as well as the potential 
confounding factor of a symptomatic response. In addi-
tion, there is no reliable biomarker for assessing disease 
progression.11 Initially used in oncology trials, a trial with 
a futility design allows for a relatively short study duration 
and smaller sample size in comparison with the typical 
phase II/III trial design.12 The futility design typically has 
a single treatment arm and tests whether a new treatment 
exceeds a pre-defined futility threshold.12 In neurolog-
ical diseases such as PD, the lack of a concurrent control 
group has led to criticism of subsequent findings from 
futility trials13 but it is possible to test for futility using a 
randomised parallel group design. There is, therefore, 
increasing interest in the use of futility trials to provide 
an efficient method for early phase studies to ascertain 
whether there is sufficient evidence to justify conducting 
larger, longer and more expensive phase III trials. The PD 
STAT trial is a phase II futility study, which aims to deter-
mine whether simvastatin has potential to reduce the rate 
of neurodegenerative decline in patients with PD.
Aims and objectives
The aim of the study is to determine whether the choles-
terol-lowering drug, simvastatin, has potential as a neuro-
protective therapy in PD. The primary objective of the PD 
STAT study is to determine whether simvastatin is clearly 
ineffective (futile) in preventing the clinical decline of PD 
as measured by the Movement Disorder Society Unified 
Parkinson’s Disease Rating Scale (MDS-UPDRS) motor 
score in patients in the OFF state.14 Secondary objectives 
are to confirm the safety and tolerability of simvastatin 
in patients with PD, to distinguish symptomatic effects of 
simvastatin from disease-modifying effects, and to eval-
uate the impact of simvastatin on activities of daily living, 
timed motor tests, cognitive ability, mood, behaviour, 
non-motor symptoms and quality of life in patients with 
moderate PD using standard validated tools of assess-
ment. The results of this study will help to determine the 
merits of conducting a larger, definitive phase III study 
to assess the neuroprotective and/or disease-modifying 
effectiveness of simvastatin.
METHODS AND ANALYSIS
This protocol is reported in accordance with the Stan-
dard Protocol Items: Recommendations for Interven-
tional Trials guidance for protocols of clinical trials.15
Trial design and setting
This is a double-blind, randomised, placebo-controlled, 
multi-centre, parallel group trial in patients with PD of 
moderate severity. There are three embedded substudies. 
Participants are individually randomised in a 1:1 ratio to 
receive either oral simvastatin or matched placebo for 
24 months. A 1-month low-dose phase (40 mg daily) is 
followed by a 23-month high-dose phase (80 mg daily) 
and treatment ends with a 2-month washout period. 
Recruitment took place between March 2016 and March 
2018, with a target of at least 198 participants progressing 
successfully to the high-dose phase of the study; 26-month 
follow-up of all participants is expected to be completed 
by May 2020. The trial design, including scheduled 
follow-up assessments, is summarised in figure 1.
A 12-month treatment period was originally consid-
ered but it was felt that this might not be long enough to 
demonstrate any disease-modifying effect; hence, partici-
pants are each treated for 24 months. Should this futility 
study have positive results, the additional collection of 
12-month outcome data, as well as outcome data collected 
at the primary endpoint of 24 months, will enable assess-
ment of any potential benefit at 12 months to assist with 
design of future studies.
The trial is being conducted in 23 National Health 
Service (NHS) Trusts across England. A list of recruiting 
sites is provided in online supplementary appendix A. A 
local principal investigator (PI), supported by at least two 
other staff members (eg, research nurse or PD specialist 
nurse), leads the conduct of the study at each partici-
pating site. Participants are followed up on an outpatient 
basis at 1 month, 6, 12, 18, 24, and 26 months post-base-
line (treatment start), with regular interim telephone 
contact.
Study population
The study population includes patients aged between 40 
and 90 years with a diagnosis of idiopathic PD, a modi-
fied Hoehn and Yahr stage of ≤3.0 in the ON medica-
tion state, and who are on dopaminergic treatment with 
experience of wearing-off phenomenon (as defined 
by the nine-item wearing-off questionnaire (WOQ)16). 
Patients are excluded if they have a diagnosis (or suspi-
cion) of another cause for their parkinsonism, or have 
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Figure 1 Scheduled follow-up assessments.
Box 1 Inclusion and exclusion criteria
Inclusion criteria
1. Diagnosis of idiopathic PD
2. Modified Hoehn and Yahr stage ≤3.0 in the ON medication state
3. Age 40–90 years
4. On dopaminergic treatment with wearing-off phenomenon
5. Able to comply with study protocol and willing to attend necessary 
study visits
Exclusion criteria
1. Diagnosis or suspicion of other cause for parkinsonism
2. Known abnormality on CT or MRI brain imaging considered to be 
causing symptoms or signs of neurological dysfunction, or consid-
ered likely to compromise compliance with study protocol
3. Concurrent dementia defined by a MoCA score <21
4. Concurrent severe depression defined by MADRS score >31
5. Prior intracerebral surgical intervention for PD including deep brain 
stimulation, lesional surgery, growth factor administration, gene 
therapy or cell transplantation
6. Already actively participating in a research study that might conflict 
with this trial
7. Prior or current use of statins as a lipid-lowering therapy
8. Intolerance of statins
9. Untreated hypothyroidism
10. End-stage renal disease (creatinine clearance <30 mL/min) or 
history of severe cardiac disease (angina, myocardial infarction or 
cardiac surgery in preceding 2 years)
11. eGFR <30 mL/min
12. History of alcoholism or liver impairment
13. Creatine kinase >1.1 × ULN
14. AST or ALT >1.1 × ULN
15. Females who are pregnant or breast feeding or of child-bearing 
potential and unwilling to use appropriate contraception methods 
while on trial treatment
16. Currently taking any medication contraindicated with simvastatin 
use
17. Any requirement for statin use
18. Regular participation in endurance or high-impact sports
19. Unable to abstain from consumption of grapefruit-based products
ALT, alanine transaminase; AST, aspartate transaminase; eGFR, 
estimated glomerular filtration rate; MADRS, Montgomery and 
Asberg Depression Rating Scale; MoCA, Montreal Cognitive As-
sessment; PD, Parkinson’s disease; ULN, upper limit of normal.
any prior use, current use, intolerance of or requirement 
for, statins. A full list of patient inclusion and exclusion 
criteria is listed in box 1.
Outcome measures
The primary outcome is the change in MDS-UPDRS part 
III motor subscale score in the OFF state between base-
line and 24 months.14 Secondary outcomes at 12, 24 and 
26 months include the following:
 ► MDS-UPDRS total score in the practically defined ON 
state
 ► MDS-UPDRS part II subscale score in the practically 
defined ON state
 ► Timed motor tests—finger tapping and timed walk 
test (10 Metre Walk Test) in the OFF state, electro-
magnetic sensor (EMS) assessment in the OFF and 
ON state
 ► Montgomery and Asberg Depression Rating Scale 
(MADRS)
 ► The Addenbrooke’s Cognitive Assessment-III
 ► Non-Motor Symptom assessment scale
 ► Parkinson’s Disease Questionnaire-39
 ► Changes in PD medication as measured by levodo-
pa-equivalent dose
 ► Cholesterol levels (total, high-density lipoprotein 
(HDL), total/HDL ratio)
 ► King’s PD pain scale
 ► EuroQoL 5D-5L health status questionnaire
 ► Safety and tolerability of trial medication by adverse 
events (AEs) review
 ► Incidence of diabetes mellitus at 24 months, using 
a glycated haemoglobin (HbA1c) level of 6.5% (48 
mmol/mol) as diagnostic of diabetes mellitus17
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Participant identification and initial telephone screening (T1)
Potentially suitable patients were identified via clinical 
lists, research registers and publicity/word of mouth. 
Patients who expressed interest in the study were sent a 
study invitation letter and participant information sheet. 
A member of the local research team subsequently tele-
phoned the patient to discuss the study further, ascertain 
further interest and establish potential eligibility for the 
study.
Consent and screening visit (V1)
The study schedule is depicted in table 1. Interested 
patients deemed to be potentially eligible for the study 
were invited to attend a local screening appointment. 
After patients had any questions answered, those who 
were willing, and appeared to meet the study eligibility 
criteria, were asked to provide written informed consent 
before proceeding with full screening for the study. 
The written informed consent process was undertaken 
by the PI or by an appropriately trained member of the 
research team as delegated by the PI, depending on local 
arrangements. Initial screening included recording of 
demographic details, medical history and concomitant 
medication. Patients completed the WOQ-9, MoCA and 
MADRS with the PI (or authorised delegate) and under-
went a physical examination by the PI (or authorised 
delegate), including assessment of modified Hoehn and 
Yahr stage. Blood samples for creatinine kinase (CK), 
aspartate transaminase (AST) or alanine transaminase 
(ALT), estimated glomerular filtration rate, cholesterol 
(HDL, total), urea, electrolytes (sodium, potassium and 
creatinine), thyroid stimulating hormone and glycated 
HbA1c were taken and analysed locally.
Calculation of cardiovascular disease risk score
National Institute for Health and Care Excellence 
(NICE) guidelines recommend that people with an esti-
mated 10-year risk of cardiovascular disease (CVD) of 
10% or more should be prioritised for a full formal risk 
assessment for consideration of statin therapy.17 QRISK2 
is a commonly used CVD risk calculator that was used in 
this study to assess whether there may be an underlying 
requirement for statin therapy.
The QRISK2 score (considering all risk factors) was 
calculated for each potential participant after their 
screening visit, by the Peninsula Clinical Trials Unit 
(CTU) at Plymouth University.18 A QRISK2 score <10% 
permitted entry to the study, assuming all other eligibility 
criteria were satisfied. Patients with a score ≥10% were 
advised to discuss the implications with their general 
practitioner (GP), but were able to be included in the 
study regardless of whether they consulted their GP or 
not, providing that they were not subsequently prescribed 
statin therapy by their GP.
Screening for type 2 diabetes
There is some evidence that long-term use of high doses 
of simvastatin may be associated with an increased risk 
of developing insulin resistance and type 2 diabetes 
mellitus,19 20 although in a recent analysis there was no 
reported evidence of a significant association at 2 years 
in patients taking a prescribed statin.21 To monitor this, 
patients were screened at baseline and month 24 using 
a glycated HbA1c level of 6.5% (48 mmol/mol) as diag-
nostic of diabetes mellitus.22
Patients with an existing diagnosis of diabetes were not 
excluded from study participation. Those presenting with 
an HbA1c≥6.5% (≥48 mmol/mol) at screening, in the 
absence of a diabetes diagnosis, were asked to discuss the 
implications with their GP before proceeding further with 
the study, and excluded if a statin was prescribed. These 
patients opting not to consult their GP were considered 
ineligible for the study, based on the potential require-
ment for statins in the future.
Final eligibility
Following the screening visit, patients who remained 
eligible and willing to participate in the study were invited 
to attend a baseline visit approximately 2 to 8 weeks after 
the screening visit. This interval enabled review of the 
screening blood results, including time for any subse-
quent GP discussions, in order to confirm final eligibility 
for the study. If more than 8 weeks had elapsed since the 
screening visit, all screening assessments were repeated 
before proceeding to the baseline visit (nine participants 
required re-screen on this basis, of whom one was deemed 
eligible).
Allocation to simvastatin or placebo
Participants were individually randomised to receive 
simvastatin or matched placebo in a 1:1 ratio. A 24-hour 
secure web-based randomisation system was created by 
the CTU in conjunction with an independent statistician 
and was accessed by research teams at local sites. Alloca-
tion used random permuted blocks, with stratification by 
site and modified Hoehn and Yahr stage (≤2.0 or 2.5–3) 
in the ‘ON’ medication state. To maintain concealment, 
the allocation was not displayed or otherwise accessible 
to the person undertaking the randomisation process. 
Following completion of the randomisation process (at 
some point between the screening and baseline visits, 
or at the baseline visit itself), a signed prescription was 
passed to the relevant hospital pharmacy so that the initial 
1-month supply of trial medication could be dispensed 
for the baseline visit.
Trial treatment
The trial treatment is an over-encapsulated simvastatin 
(40 mg) tablet back-filled with microcrystalline cellulose 
magnesium stearate, or identically presented matched 
placebo containing microcrystalline cellulose magne-
sium stearate only. Capsules are packaged in plastic screw 
neck bottles with child-resistant, tamper-evident lids. 
Each bottle contains 100 capsules and has a unique four-
digit number with an expiry date displayed on a label that 
meets the current regulatory requirements. Participants 
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are provided with a 1-month supply of trial medication 
at baseline, a 5-month supply at the month 1 visit, and a 
6-month supply at months 6, 12 and 18 visits. Participants 
are asked to return all empty, full or partially used medi-
cation bottles at each study visit. These are returned to 
the local site pharmacy for capsule count as part of the 
assessment of compliance with study treatment.
Baseline visit (V2)
Participants attended their baseline visit in the practi-
cally defined OFF state (see below) and underwent a 
series of assessments (see table 1) before being invited 
to take their usual PD medications. Further assessments 
were then undertaken in the ON state before participants 
were provided with a 1-month supply of trial medication 
(40 mg daily dose or placebo) for the initial low-dose 
phase. Participants were also provided with a paper-based 
diary in which to record any dose alterations, concom-
itant medications or AEs. The diary was intended to 
serve as an aide-memoire, with participants being asked 
to bring their completed diary to each study visit to aid 
Case Report Form completion by the local research team. 
Participants were advised to contact the local research 
team promptly should they develop unexplained muscle 
pain, tenderness or weakness.
Participant follow-up and data collection
Participant follow-up is via a mixture of clinic visits and 
telephone contacts. Clinic visits are held at 1 month (V3), 
then 6, 12, 18, 24 and 26 months (V4–V8) post-baseline. 
The 12-month, 24-month and 26-month visits require 
attendance in the OFF state, followed by further assess-
ments on the same day in the ‘ON’ state after the partic-
ipant has taken his/her usual PD medication—as for 
baseline (V2). Telephone contacts between visits are made 
at 2 weeks (T2), and then at 4, 8, 10, 14, 16, 20 and 22 
months (T3–T9) to identify any compliance problems, 
AEs or changes to participants’ routine medication. Addi-
tional telephone contacts may be made, as required, at 
the discretion of the local research team and specifically 
in the event of abnormal blood results being identified at 
any stage during the trial.
Practically defined ‘OFF’ and ‘ON’ state
Participants are asked to attend baseline, 12-month, 
24-month and 26-month study visits in the OFF state, 
having omitted their routine PD medication. To facilitate 
attendance, these visits are scheduled in the morning, 
and OFF assessments take approximately 30 min to 
complete. Short-acting PD medications are omitted 
from 1800 hours on the day before the clinic visit. Long-
acting agents are omitted for the entire day before the 
clinic visit and also on the day of the visit itself. The local 
research team is able to make arrangements to provide 
the participant with a prescription for relevant supportive 
medications (eg, zopiclone/zolpidem for night sedation, 
paracetamol for pain relief and/or diazepam for treat-
ment of anxiety) as necessary. Participants may also be 
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Table 2 AST/ALT monitoring outcomes and action required
Observation Action required Repeat observation Action required
AST/ALT>3xULN Repeat sample within 1 
week
AST/ALT>4xULN Stop study treatment temporarily
AST/ALT>2 xULN but ≤4 x ULN Repeat again within 3 weeks. 
If remains >2 ×ULN stop study 
treatment temporarily
AST/ALT>2 xULN but ≤3xULN Repeat again within 3 
weeks
AST/ALT>3xULN Stop study treatment temporarily
AST/ALT>2 xULN but ≤3xULN Repeat again within 3 weeks. 
If remains >2 ×ULN stop study 
treatment temporarily
ALT, alanine transaminase; AST, aspartate transaminase; ULN, upper limit of normal.
prescribed dispersible Madopar as a rescue medication 
to be taken in the event of severe difficulty with OFF state 
symptoms, but this would necessitate abandonment of 
the study visit. The visit can be rescheduled if the patient 
has been unable to attend in the OFF state. If the further 
attempt at attending in the OFF state fails, the partici-
pant is withdrawn from the study. The delivery of OFF 
state assessments is challenging, but we are managing this 
with appropriate interaction with, and training of, study 
teams, encouraging them to provide support for patients, 
such as the use of taxis to facilitate visit attendance and 
the offer of home visits if necessary.
Dose adjustments
If the participant was able to tolerate the initial low-dose 
phase of trial medication for 4 weeks, the prescription 
was increased to 80 mg daily at the 1-month clinic visit. 
At the 24-month visit, participants stop their trial medi-
cation and a 2-month washout period follows. The final 
visit at 26 months will be used to differentiate whether any 
benefit may have been symptomatic.
Participants who were unable to tolerate the 40 mg 
dose during the first month due to unwanted symptoms, 
or who fulfilled the stopping criteria (see later), had 
their trial treatment permanently discontinued but were 
invited to continue with the study assessments.
During the higher-dose maintenance phase, partici-
pants who are unable to tolerate the 80 mg dose of study 
medication due to unwanted symptoms (but who do not 
fulfil the stopping criteria) may have their dose reduced 
to 40 mg daily. Participants may continue on the 40 mg 
dose for the remainder of the trial or, at the discretion 
of the local PI, may later be re-challenged with the 80 mg 
dose after resolution of their symptoms.
Blinding
This is a double-blind study, hence the participants, trial 
management team, investigator site teams and site phar-
macy staff are blind to treatment allocation throughout 
the trial. In the event of a potential Suspected Unex-
pected Serious Adverse Reaction (SUSAR) to the trial 
medication, unblinding will be undertaken by the 
sponsor in accordance with the regulatory requirements. 
Unblinding may also be performed at the request of a 
senior clinician responsible for the care of a trial partici-
pant but such requests are likely to occur only in the case 
of a serious adverse clinical event and are expected to be 
rare. The Data Monitoring Committee (DMC) is able to 
review unblinded data as required.
Since the PI and other ‘treating’ site team members 
have access to participants’ blood results and review 
all reported AEs, a separate ‘assessing’ member of the 
research team undertakes the MDS-UPDRS and other 
outcome assessments after appropriate training. The 
same outcome assessor is used at all visits for an individual 
participant and sites are requested to identify back-up 
personnel to cover staff absences and avoid cross-over 
of ‘assessing’ and ‘treating’ team members. Telephone 
follow-up calls are not made by outcome assessors.
Participant monitoring
At each study visit or telephone call, participants are asked 
about any AEs experienced and, dependent on reported 
symptoms, may be asked to provide a blood sample to 
check CK and/or AST/ALT levels. If a raised AST/ALT 
is observed in the absence of a CK result, the CK should 
be checked. Tables 2–4 outline the possible outcomes and 
any action required.
If the participant reports jaundice or new or unusually 
severe nausea, malaise or lethargy, an AST/ALT level 
should be checked (table 2). If study treatment needs 
to be stopped temporarily, AST/ALT should be checked 
again after 6 weeks, and then action taken in accordance 
with table 3.
If the participant reports new or unusually severe 
muscle pain, tenderness or weakness, the CK level should 
be checked (table 4).
AEs may also be reported to the research team outside 
of a participant’s scheduled clinic visit, either by the 
participant, non-study clinician or other informant by 
contacting the trial centre.
Stopping criteria for discontinuation of trial treatment
The defined stopping criteria for the discontinuation of 
trial medication are:
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Table 3 AST/ALT monitoring outcomes and action required 6 weeks after temporary stop of study treatment
Observation Action required Subsequent action required
AST/ALT>1.5xULN Stop study treatment 
permanently
Repeat every 3 weeks until AST/ALT reverts to normal (ie, 
≤1.5 xULN)
AST/ALT≤1.5xULN Study treatment can be 
restarted
Repeat twice at 3-week intervals. AST/ALT must remain 
≤2 xULN, otherwise study treatment should be stopped 
permanently
ALT, alanine transaminase; AST, aspartate transaminase; ULN, upper limit of normal.
Table 4 CK monitoring outcomes and action required
Observation Action required Repeat observation Action required
CK >5xULN Stop study treatment 
permanently
Repeat sample within 1 week
Repeat every 3 weeks until CK 
reverts to normal (ie, ≤3 xULN)
Repeat every 3 weeks until CK 
reverts to normal (ie, ≤3 xULN)
CK >4 xULN but ≤5 xULN 
that cannot be explained (ie, 
trauma, heavy exercise, etc)
Repeat sample within 1 week CK remains >4 xULN but ≤5 
xULN
Stop study treatment 
temporarily
  Check CK again in 6 weeks
 ►  If CK>3 xULN stop study 
treatment permanently
 ►  If CK≤3 xULN study 
treatment can be restarted 
with two further repeats 
at 3-week intervals (at 
which CK must remain 
≤3 xULN otherwise study 
treatment must be stopped 
permanently)
CK, creatine kinase; ULN, upper limit of normal.
1. Abnormalities in CK or ALT/AST fulfilling stopping 
criteria as outlined above, OR
2. New severe muscular symptoms (progressive or per-
sistent), not attributable to other cause, which in the 
opinion of the PI may be related to the study medica-
tion even in the absence of abnormal CK, OR
3. Onset of a clinical condition for which prescription of 
a statin is indicated.
Pharmacovigilance
Safety and tolerability of the trial treatment are monitored 
throughout the study by means of regular clinic visits and 
interim telephone follow-up review of all participants. All 
serious adverse events (SAEs) are recorded and reported, 
whether they are deemed related to the trial treatment 
or not. Quarterly summaries of all SAEs are provided to 
the DMC and study sponsor. Any potential SUSAR will be 
reported immediately to the sponsor who will have the 
facility to unblind the treatment allocation independently 
of the trial team and report onwards as necessary.
Non-SAEs deemed possibly, probably or definitely 
related to trial treatment are also recorded, monitored 
by the Trial Management Group (TMG) and reported to 
the DMC.
Embedded sub-studies
The three embedded substudies will be described in more 
detail in separate publications. The ‘Experience of Trial 
Participation’ substudy aims to develop an understanding 
of the barriers and facilitators to participating in clinical 
trials for people living with PD. It includes a quantitative 
component (feedback surveys) for all participants and 
a qualitative component (semistructured interviews and 
focus groups) in a sample of participants and their carers. 
Part of this substudy involves an evaluation of The Cure 
Parkinson’s Trust’s Charter for Clinical Trials in Parkin-
son’s, which aims to set standards of practice for both 
participants and clinicians involved in clinical trials for 
PD. All patients approached for the PD STAT study were 
provided with a copy of this charter and asked to provide 
feedback on its usefulness.
The ‘genetic substudy’ aims to identify the genetic 
markers that may be associated with PD disease course, 
severity or variation in treatment responsiveness. PD 
STAT participants are asked to provide separate written 
informed consent, followed by collection of two 10 mL 
blood samples, usually at the 12-month clinic visit. One 
sample is sent to University College London Neuroge-
netics Department. The inherited materials (DNA and 
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genes) are extracted from the sample and stored in a 
biobank within the Institute of Neurology. The second 
sample is sent to the Genetic Support Support Services, 
Culture Collections, Public Health England laboratory 
for preperation and storage of peripheral blood lympho-
cytes and potential future cell lines.
The ‘EMS measurement’ substudy is an exploratory 
study conducted in a subset of participants. It aims to eval-
uate the use of the EMS (Polhemus Inc.) in the measure-
ment of bradykinesia and tremor and is completed 
alongside the MDS-UPDRS upper limb motor assess-
ments at the 12-month and 24-month visits. Participants 
are required to wear the sensors on the index finger and 
thumb when performing the assessments, visual assess-
ments are conducted as normal by the assessor.
Patient and public involvement
Patient and public involvement (PPI) representatives are 
members of both the TMG and Trial Steering Committee 
(TSC). They were involved in the design of the study and 
reviewed and advised on all participant-facing study docu-
mentation; they will also be closely involved in dissemina-
tion of results to participants and patient groups.
Study management
The study sponsor organisation is the University Hospi-
tals Plymouth NHS Trust, Derriford, Plymouth PL6 5FP. 
Day-to-day trial management is administered through 
the United Kingdom Clinical Research Collaboration 
(UKCRC)-registered Peninsula CTU at Plymouth Univer-
sity. The CTU conducts central and site monitoring 
in accordance with a risk-based monitoring plan and 
the study sponsor may audit trial conduct as deemed 
appropriate.
The TMG, which includes two patient members, meets 
regularly to monitor and discuss the progress of the trial, 
and to address any issues that may arise. The TSC, which 
includes an independent chair and two PPI members, 
meets once or twice a year to oversee the conduct of the 
trial. An independent DMC, comprising two independent 
clinicians and a statistician, meets at similar intervals to 
the TSC to monitor safety and ethical issues, including 
any participant drop-outs and overall data completeness. 
The agreed roles and responsibilities of both committees 
are set out in written charters.
Data management and Confidentiality
Research teams at all sites ensure that participants’ 
anonymity is maintained for all documents.
Data are collected and stored in accordance with the 
Data Protection Act, 1998 and General Data Protection 
Regulation, 2018. Within the CTU, pseudonymised 
paper-based study data are stored in locked filing cabi-
nets within a locked office. Electronic records are stored 
in a Structured Query Language (SQL) server database, 
stored on a restricted access, secure server maintained 
by the University of Plymouth. The study website is 
encrypted using Secure Sockets Layer (SSL). Study data 
are double-data entered on to a password-protected data-
base within the CTU, with copies retained at the relevant 
study site. Double-entered data are compared for discrep-
ancies using an established procedure to verify data entry. 
Discrepant data are verified using the original paper data 
sheets. Direct access to the trial data is overseen by the 
CTU, and restricted to members of the research team and 
the CTU, with access granted to the sponsor on request. 
Copies of study data retained at study sites are securely 
stored for the duration of the study prior to archiving.
Sample size
As this study has a futility design, the direction of the 
hypotheses is different from that in traditional phase II 
efficacy or effectiveness trials. The study sample size has 
been calculated based on testing the null hypothesis that 
simvastatin is not futile, in terms of the primary outcome. 
If at the end of the study there is evidence to reject the 
null hypothesis, then simvastatin will be considered to be 
futile for a phase III study.
The minimum clinically important difference in UPDRS 
motor score has been estimated to be 2.3–2.7 points.23 
The null hypothesis (H0) in this futility study is that the 
mean MDS-UPDRS part III change score (between base-
line and 24 months) for the simvastatin group is at least 
three points better (ie, smaller, as higher MDS-UPDRS 
scores are worse) than the corresponding mean change 
in the placebo group. The alternative hypothesis (HA) is 
that the mean MDS-UPDRS part III change score for the 
simvastatin group is not at least three points better. This 
can be written mathematically as:
H0: μs ≤ μp – 3 versus HA: μs > μp – 3
where μs is the expected mean MDS-UPDRS part III 
change score from baseline to 24 months for the simvas-
tatin group and μp is the corresponding expected mean 
change for the placebo group. Given this hypothesis, a 
one-sided test (and associated significance level, alpha) 
is appropriate.
In futility studies, the error probabilities are inter-
preted differently from those in traditional efficacy/
effectiveness studies. The type 1 (alpha) error pertains 
to recommending that an effective treatment should not 
be considered for a phase III study and the type 2 (beta) 
error pertains to recommending that an ineffective treat-
ment should be considered for a phase III study.24 Given 
these different interpretations, alpha and beta are chosen 
relative to the futility design-based hypotheses: in this 
study, the one-sided alpha is set at 10% and beta at 20% 
(ie, 80% power).24 Under these design parameters, there 
is a 20% chance of failing to identify that simvastatin is 
ineffective.
Based on available data at the time of planning the PD 
STAT study, the expected mean increase in MDS-UPDRS 
part III from baseline to 12 months in the placebo group 
is 2.2 points, with SD 7.3 points.25 Assuming that this 
increase in MDS-UPDRS part III is linear over time, gives 
an expected mean increase from baseline to 24 months of 
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4.4 points in the placebo group, with an assumed slightly 
inflated SD over this period of 7.5 points.
The null hypothesis H0: μs ≤ μp – 3 can be stated equiv-
alently as H0: μs – μp ≤ −3. To test this hypothesis, and 
assuming μp is 4.4 points, it is assumed that μs is 1.4 points 
(ie, 4.4−3). Based on a two-sample t-test with a 10% 
one-sided alpha, it is estimated that 24-month follow-up 
data are required from 57 participants per allocated 
group to provide 80% power to reject the null hypothesis 
and declare futility.
The initial calculated sample size was inflated twice. 
First, to allow for a small proportion of participants allo-
cated to the simvastatin group to stop taking the trial medi-
cation during the initial 4 week low-dose phase. Assuming 
that this proportion is 15%, the previous sample size is 
inflated by a factor of (1–0.15)−2, to give 79 participants 
per group.26 Second, the sample size was adjusted to 
allow for a (non-differential) loss to follow-up rate by 24 
months of 20%. Accordingly, the sample size was further 
inflated by a factor of (1–0.2)−1, to give a sample size of 99 
participants per group and a total recruitment target of 
198 participants.
Statistical analysis
The primary analyses are all pre-specified and a detailed 
statistical analysis plan will be drafted and agreed by the 
DMC and signed off by the independent statistician on 
the TSC, prior to commencement of analyses. The study 
will be reported following the principles of Consolidated 
Standards Of Reporting Trials guidelines.27–31 There is no 
planned interim analysis for this study. Primary analyses 
will be on a modified intention-to-treat (ITT) basis. The 
ITT evaluable sample will include all participants who 
are randomised and who commence on the higher-dose 
phase of the study. As this is a phase II study, no imputa-
tion of missing data is planned for the primary analysis 
and so the ITT sample for the primary analysis of the 
primary outcome will include participants with baseline 
and 24-month MDS-UPDRS part III scores.
The statistical analyses will be undertaken blinded to the 
allocated group. The primary analysis will be a between-
group comparison of mean change in MDS-UPDRS 
part III from baseline to 24 months. Specifically, a linear 
regression model will be fitted to MDS-UPDRS part III 
scores at 24 months, with allocated treatment group, base-
line MDS-UPDRS part III score, the stratification variable 
(modified Hoehn & Yahr stage), gender and age at baseline 
included as covariates. Scores will be appropriately trans-
formed if necessary. In the primary analysis of the primary 
outcome, if the p value <0.1 from the regression model 
testing the null hypothesis that the treatment effect is <-3, 
then the null hypothesis that simvastatin is not futile will be 
rejected and simvastatin will be considered to be futile for 
a phase III study. For completeness, the two-sided 80% CI 
(confidence interval) for the estimated treatment effect will 
also be presented, although only the upper bound of the 
CI is of relevance when assessing for futility. If the upper 
bound of the CI is lower than −3, there will be evidence to 
consider simvastatin for a phase III study.
Consideration will be given to a secondary analysis of 
the primary outcome on a per-protocol basis. If a sufficient 
number of participants drop back down to the lower dose of 
simvastatin, consideration will be given to a subgroup anal-
ysis of the effect of dose. These, and any other secondary 
analyses, such as comparing participant characteristics of 
responders and non-responders, will be discussed with the 
DMC and included in the agreed statistical analysis plan.
Secondary continuous outcomes will be compared 
between allocated treatment groups in a similar manner, 
although will not be statistically tested for futility; instead 
the focus will be on providing appropriate summary statis-
tics and CIs for the between-group differences. Ordered 
categorical outcomes will be analysed using ordinal regres-
sion analysis. Analysis of AEs will be on a per-protocol basis.
Ethics and dissemination
The protocol has been approved by the North East—
Newcastle and North Tyneside 2 Research Ethics Committee 
(REC Reference: 15/NE/0324). The trial is conducted 
in accordance with the study protocol, the principles of 
the Declaration of Helsinki, International Conference on 
Harmonisation of Good Clinical Practice and the Medi-
cines for Human Use (Clinical Trials) Regulations, 2004. 
The trial has been adopted by the National Institute for 
Health Research (NIHR) Clinical Research Network and 
has relevant local NHS research approvals. The study is 
sponsored by University Hospitals Plymouth NHS Trust and 
managed by the UKCRC-registered Peninsula CTU.
After the end of the study, pseudonymised information 
collected during the study will be made available to other 
researchers under an appropriate data sharing agree-
ment, but it will not be possible to identify participants 
personally from any information shared.
Following analysis of the data, the results will be dissem-
inated through publication of articles in peer-reviewed 
journals and presentations at local, national and inter-
national scientific meetings. A lay summary of the study 
results will be prepared with assistance from our patient 
TMG members and made available to study participants, 
PD charities and relevant support groups for wider 
dissemination among people with PD and their families.
DISCUSSION
There is currently no neuroprotective agent proven to 
slow or reverse the progression of PD. This phase II trial 
is required to inform the decision to progress to a defin-
itive phase III randomised controlled trial evaluating the 
effectiveness of simvastatin as a neuroprotective agent to 
treat PD. In addition to this, the study will generate other 
important outputs related to trial delivery and how trial 
experience can be improved from the perspective of the 
participants.
This study has a number of strengths: it starts a shared 
resource with other studies in the LCT initiative with the 
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pharmacogenetics substudy, and the EMS substudy provides 
a platform for evaluating a novel outcome measure based 
on wearable technology for neuroprotective studies that 
can be used to inform future evaluations. PD STAT impor-
tantly demonstrates that a multi-centre trial delivery plat-
form exists within the UK to deliver a study of reasonably 
long duration, engaging patients with PD and clinicians, 
which will strengthen delivery of future similar studies.
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